Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Operating Leases (2019 - 2025)

Historic Operating Leases for Marimed (MRMD) over the last 7 years, with Q3 2025 value amounting to $8.8 million.

  • Marimed's Operating Leases fell 966.39% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year decrease of 966.39%. This contributed to the annual value of $7.5 million for FY2024, which is 1071.56% down from last year.
  • Latest data reveals that Marimed reported Operating Leases of $8.8 million as of Q3 2025, which was down 966.39% from $9.1 million recorded in Q2 2025.
  • Over the past 5 years, Marimed's Operating Leases peaked at $10.6 million during Q1 2023, and registered a low of $4.2 million during Q4 2022.
  • Over the past 5 years, Marimed's median Operating Leases value was $8.5 million (recorded in 2023), while the average stood at $7.6 million.
  • Its Operating Leases has fluctuated over the past 5 years, first plummeted by 2001.64% in 2021, then surged by 10261.2% in 2023.
  • Over the past 5 years, Marimed's Operating Leases (Quarter) stood at $4.6 million in 2021, then fell by 8.77% to $4.2 million in 2022, then soared by 102.61% to $8.5 million in 2023, then decreased by 10.72% to $7.5 million in 2024, then rose by 16.77% to $8.8 million in 2025.
  • Its last three reported values are $8.8 million in Q3 2025, $9.1 million for Q2 2025, and $9.4 million during Q1 2025.